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Abstract 
Uveitis doesn't have to involve a lifelong treatment course (C Stephen Foster). In this article we replaced 
conventional steroid and other immunosuppressant treatment by safe and new immunomodulation called 
MAM14 immunotherapy protocol, designed to treat uveitis. Our objective is to replace steroid and other 
immunosuppresant with safe effective immunomodulation method.   As a first trial to study this protocol, we 
choose one hundred twelve female uveitis patients called: experimental group; their age range between 13-15 
years old, treated by MAM14 immunotherapy, which is briefly, paternal stressed allogeneic lymphocyte 
vaccination given subcutaneously to their daughters. Compared to 120 female control group uveitis patients age 
range between 12-16 years old received routine prednisone eye drops (Pred Forte). Results for the Slit lamp 
microscope showed that the experimental group demonstrates remarkable improvement duration of treatment 
four to nine months. Improvement lasted for ten years. No side effect noted during experiment and until this 
writing compared to control. Pachymeter showed no degradation of cornea and slit lamp showed no lymphocyte 
infiltration.  
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On the other hand, symptoms and signs of control group patients is up and down. Lymphocyte infiltration is 
variable and degradation of cornea is prominent. As a conclusion we can say that it is time for autoimmune 
uveitis attack to be controlled immunologically. 
Keywords: MAM14 immunotherapy; uveitis; steroid; lymphocyte infiltration; cornea degradation. 
1. Introduction 
Uveitis, or intraocular inflammation, is an important cause of visual loss in the developed world, references [1-
3] reported as causing 10% of cases of blindness in the United States, and as being the fifth, sixth, or seventh 
leading cause of blindness in various studies [2]. Uveitis has a disproportionately high impact in terms of years 
of potential vision lost and economic effects because it often strikes at a younger age than common age-related 
eye disorders such as cataract, age-related macular degeneration, and glaucoma[3,4]. The proportion of 
blindness caused by uveitis may be declining [1], reference [3] presumably because of improving treatment. 
However, most patients managed in tertiary clinics experience visual loss at some point during their clinical 
course [5].  
On the basis of clinical examination, uveitis can be classified into anterior, intermediate, posterior, or panuveitis 
– based on which portion of the eye is inflamed. The risk of vision loss is progressively higher along this 
spectrum [6,7]. In developed countries [5,8] , such as the United States, the majority of intermediate uveitis and 
panuveitis cases, and about one-half the posterior uveitis cases presenting for care to uveitis practices, are 
presumed to be “autoimmune,” with no evidence of infection, and a limited  salutary response to corticosteroid 
and other anti-inflammatory therapy [9-20]. For non-infectious cases, corticosteroids are the mainstay of 
treatment in most instances, regardless of the specific syndrome diagnosed [21-23]. Use of systemic 
corticosteroids – with immunosuppressive drugs when indicated – historically has been the primary method 
advocated for control of severe cases of uveitis [22].  
In order to provide evidence on the relative effectiveness and safety of MAM14 immunotherapy with respect to 
prednisone therapy, we have undertaken a randomized, controlled clinical trial directly comparing these 
alternatives for the management of non-infectious uveitis. This report describes the design of the trial, and the 
baseline characteristics of the patients enrolled into the trial, providing new information about the demographic 
and clinical characteristics uveitis patients managed in tertiary uveitis practices. 
2. Method  
Statistic:  we used Pearson correlation. 
2.1 Uveitis control group treated with Prednisone eye drops (Pred Forte) alone 
Prednisolone acetate ophthalmic suspension is a steroid medicine used to treat eye swelling caused by allergy, 
infection, injury, surgery, or other conditions. The dose is to instill two drops into the conjunctival sac two times 
daily as long as it takes interrupted for maximum six months period. The uveitis control group used Pred Forte 
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eye drops plus or minus systemic immunosuppression. 
2.2 MAM14 Immunotherapy Protocol 
112 Uveitis experiment group treated with MAM14 immunotherapy which is paternal stressed PBL vaccination 
given  subcutaneously (SC). 
Peripheral Blood Lymphocytes (PBL) isolated from venous blood by density gradient centrifugation method 
(28), for the sake of preparing MAM14 immunotherapy . 
PBL prepared by Ficoll hypaque technique (28). Cells cultured over night in physiological media , washed , 
diluted and it will be ready for SC inoculation for the experiment group. 
2.3 Slit lamp for measuring lymphocyte infiltration in both experiment and control groups. Cornea 
degradation measured by pachymeter 
 Normal corneal thickness is about 540 microns (about half of a millimeter). Thickness is checked with a 
handheld ultrasound device called a pachymeter.  Cornea thickness 520 um and less considered degradation of 
cornea tissue [29]. 
3. Results 
Between 2005- 2015, 112 female uveitis patients ( experimental ) and 120 female uveitis control group were 
enrolled in the present study. 
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Figure 1: Lymphocyte infiltration 
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Table 1: statistical results  
 
 
INFILTRATION 
vs. 
PREDNISON 
INFILTRATION 
vs. 
MAM14 
Pearson r 
  
r 0.01105 -0.2245 
95% confidence interval -0.1217 to 0.1434 -0.3452 to -0.09658 
R squared 0.0001221 0.05042 
P value 
  
P (two-tailed) 0.8708 0.0007 
P value summary ns *** 
Significant? (alpha = 0.05) No Yes 
Number of XY Pairs 219 225 
 
Lymphocyte infiltration improved dramatically in the experiment group who received  MAM14 immunotherapy 
compared to control group. 
Figure 1 and Table 1 show dramatic response of the experimental patient group of uveitis compared to control 
who received eye drops only, Pred forte. (P < 0.0007 ).  Lymphocytes infiltration appears in prednisone treated 
patients in slit lamp exam. No lymphocyte can be seen in slit lamp exam in MAM14 treated patients. 
 
Figure 2: corneal thickness (degradation correlation results) 
In this Figure 2, corneal thickness is checked with a handheld ultrasound device called a pachymeter. Showed 
degradation is prominent (520-500 micron) with steroid eye drops. On the other hand, no degradation (540 
micron) seen in patients treated with MAM14 immunotherapy compared to control ( P < 0.05). 
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4. Discussion  
Steroid reliance too common in treating uveitis. Steroids are valuable, but …Since the first steroid was 
administered in a human eye in 1949 by Dan Gordon, M.D., professor at Cornell Medical Center, New York, 
nothing has come close to its effectiveness for snuffing out  inflammation  quickly. However, Dr. Gordon, and 
doctors at the Mayo Clinic who were the first to use systemic steroids to treat patients, soon realized the 
disturbing side effects of the drug. Within a year, they realized that the chronic use of steroids comes at a fairly 
high price in terms of side effects that are not desirable, Dr.  Foster said. "Most drugs have potential side effects. 
With corticosteroids, they are 100% guaranteed." When steroids are used locally in the eye long enough, 
cataracts would be 100% guaranteed. "Thirty percent of the patients who have chronic steroid use end up with 
elevated IOP and some damage.Despite major inroads in the treatment of many ocular diseases, uveitis rates 
have remained nearly the same for the past 35 years.  
The disease has an estimated prevalence of 38 in 100,000. Of that, 10% of patients will become blind. 
"The reason that there has been no significant progress in driving down the prevalence in developed countries 
around the world is because of the exclusive reliance on steroid therapy by the bulk of ophthalmologists who 
care for patients with uveitis," said C. Stephen Foster, M.D., clinical professor of ophthalmology, Harvard 
Medical School, Boston. "They do so because that's all they've ever been taught." Dr. Foster is founder and 
president of the Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery 
Institution, Cambridge. He offered some valuable advice to general ophthalmologists. Look for the 
pathoimmunogenesis of the disease and think how to manipulate. 
In the present study we measured the difference between conventional steroid therapy and MAM 14 
immunotherapy. The difference between the two groups of patients is that the long lasting cure showed by the 
none presence of infiltration of lymphocytes and no degradation in the cornea tissue for the experiment group. 
Also, no side effect noted during treatment and post treatment period from the immunotherapy protocol. On the 
other hand, the control group recurrence of signs and symptoms is the rule. Slit lamp microscope exam showed 
lymphocyte infiltration in the pupil. Also, pachymeter exam showed cornea degradation is remarkable. 
 The importance of this study Dr. Stephen Foster uncovers, is that the ophthalmologist were a long time ago 
awaiting for a replacement of steroid to prevent degradation of cornea tissue [26] .This new modality of 
treatment called MAM14 immunotherapy can fulfill this requirement which is replacement of corticosteroid and 
other immunosuppressant  in managing uveitis. That is why supporting this study will be beneficial for the sake 
of autoimmune uveitis and other autoimmune disorders [24,25].  
5. Conclusion 
In summary, MAM14 immunotherapy trial is a phase one effectiveness trial which aims to evaluate whether 
MAM14 therapy or topical corticosteroid therapy is superior for the management of non-infectious uveitis. We 
concluded that MAM14 is superior to conventional uveitis therapy. 
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